Humulin M3 Kwikpen (Mixture 3) (Insulin Human)

Humulin M3 Kwikpen (Mixture 3) is prescribed for controlling blood glucose in adults with diabetes.

• Type 1 diabetes mellitus, when rapid‑acting insulin is required.
• Type 2 diabetes mellitus, as part of an individualized insulin regimen.
• Adjunct to diet, exercise and other antidiabetic agents to achieve target glycaemic levels.
• Administration before meals to reduce post‑prandial glucose excursions.
• Use in patients who prefer a pre‑filled pen device for convenient dosing.

• Insulin human binds to insulin receptors on cell membranes, activating the intrinsic tyrosine kinase activity of the receptor. This triggers downstream signaling pathways, including the phosphatidylinositol‑3‑kinase (PI3K) cascade, which promotes translocation of glucose transporter type 4 (GLUT4) to the cell surface. The result is increased glucose uptake in muscle and adipose tissue and reduced hepatic glucose production, thereby lowering circulating blood glucose.

Adverse reactions to Humulin M3 Kwikpen can vary in frequency and severity.

Common

• Hypoglycaemia, ranging from mild to severe.
• Injection‑site pain, redness or swelling.
• Lipodystrophy or lipohypertrophy at repeated injection sites.
• Transient weight gain.
• Localised allergic skin reactions such as itching or rash.

Serious

• Severe hypoglycaemia with loss of consciousness.
• Anaphylactic reaction, including airway swelling and difficulty breathing.
• Significant hypokalaemia.
• Generalised oedema or fluid retention.
• Urticaria or angio‑edema.

When prescribing or using Humulin M3 Kwikpen, clinicians and patients should consider several safety considerations.

• Risk of hypoglycaemia, especially with missed meals or increased physical activity.
• Adjust dose in renal or hepatic impairment.
• Monitor blood glucose regularly during therapy initiation and dose changes.
• Use with caution in pregnancy and lactation; benefits must outweigh risks.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Educate patients on proper injection technique to prevent lipohypertrophy.
• Store the pen according to manufacturer instructions and discard after the indicated period.

Humulin M3 Kwikpen may interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that may mask hypoglycaemia symptoms.
• Monoamine oxidase‑A (MAO‑A) inhibitors that can potentiate insulin’s hypoglycaemic effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk.
• Corticosteroids, thiazide diuretics, or sympathomimetics that raise blood glucose.
• Alcohol consumption, which can cause delayed hypoglycaemia.
• Thyroid hormones, which may alter insulin requirements.